

Appl. No. 10/633,808
Amdt. dated Aug. 9, 2005
Reply to Office action of Oct. 10, 2005

AMENDMENTS TO THE CLAIMS

In the claims, please cancel claims 12 and 22-25 and amend claims 1 as follows:

1. (currently amended) A composition for targeting hepatocytes comprising: a T7 ligand covalently attached to a compound, wherein,
 - a) said T7 ligand is selected from the group consisting of: T7 phage, modified T7 phage, T7 p17 protein, modified T7 p17 protein, T7 p17 derived peptide, T7 p17 rod domain, T7 p17 coiled coil domain, SEQ ID 1, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 17, SEQ ID 18, SEQ ID 19, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 23, SEQ ID 24, and a peptide or synthetic peptide analog derived from SEQ ID 1, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 17, SEQ ID 18, SEQ ID 19, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 23, or SEQ ID 24; and
 - b) said compound is selected from the [[list]] group consisting of: drug, component of a complex and polynucleotide.
2. (canceled)
3. (previously presented) The composition of claim 1 wherein the drug comprises interferon.
4. (canceled)
5. (previously presented) The composition of claim 1 wherein the complex consists of a liposome.
6. (previously presented) The composition of claim 1 wherein the complex consists of a polyplex.
7. (previously presented) The composition of claim 1 wherein the complex consists of a lipopolyplex.
8. (previously presented) The composition of claim 1 wherein the complex comprises a polynucleotide.
9. (original) The composition of claim 8 wherein the polynucleotide consists of an expression cassette.
10. (original) The composition of claim 8 wherein the polynucleotide consists of an RNA.
11. (previously presented) The composition of claim 1 wherein the polynucleotide consists of an RNA function inhibitor.
12. (canceled)

Appl. No. 10/633,808
Amdt. dated Aug. 9, 2005
Reply to Office action of Oct. 10, 2005

13. (original) The composition of claim 1 wherein the T7 ligand contains a functional group.
14. (original) The composition of claim 13 wherein the functional group consists of a thiol.
15. (original) The composition of claim 14 wherein the thiol consists of a cysteine.
16. (original) The composition of claim 13 wherein the functional group consists of biotin.
17. (original) The composition of claim 13 wherein the functional group consists of streptavidin.
18. (canceled)
19. (canceled)
20. (original) The composition of claim 1 wherein the T7 ligand is attached to the compound via a linker.
21. (previously presented) The composition of claim 20 wherein the linker consists of a polyethylene glycol.
22. (canceled)
23. (canceled)
24. (canceled)
25. (canceled)
26. (canceled)
27. (original) The composition of claim 1 wherein the T7 ligand consists of: T7 ligand-cysteine-PDP-streptavidin.
28. (original) The composition of claim 1 wherein the T7 ligand consists of T7 ligand-PEG-biotin.
29. (currently amended) A pharmaceutical preparation comprising: a compound selected from the [[list]] group consisting of: drug, component of a complex and polynucleotide covalently attached to a T7 ligand selected from the group consisting of: T7 phage, modified T7 phage, T7 p17 protein, modified T7 p17 protein, T7 p17 rod domain, T7 p17 coiled coil domain, SEQ ID 1, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 17, SEQ ID 18, SEQ ID 19, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 23, SEQ ID 24, and a peptide or synthetic peptide analog derived from SEQ ID 1, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 17, SEQ ID 18, SEQ ID 19, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 23, or SEQ ID 24.

Appl. No. 10/633,808
Amdt. dated Aug. 9, 2005
Reply to Office action of Oct. 10, 2005

30. (currently amended) A composition for targeting hepatocytes *in vivo* comprising: a T7 ligand covalently attached to a compound, wherein
- a) said T7 ligand is selected from the group consisting of: T7 phage, modified T7 phage, T7 p17 protein, modified T7 p17 protein, T7 p17 rod domain, T7 p17 coiled coil domain, SEQ ID 1, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 17, SEQ ID 18, SEQ ID 19, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 23, SEQ ID 24, and a peptide or synthetic peptide analog derived from SEQ ID 1, SEQ ID 14, SEQ ID 15, SEQ ID 16, SEQ ID 17, SEQ ID 18, SEQ ID 19, SEQ ID 20, SEQ ID 21, SEQ ID 22, SEQ ID 23, or SEQ ID 24; and
- b) said compound is selected from the [[list]] group consisting of: drug, component of a complex and polynucleotide.